Horizon Europe European Union
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · European Union
Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
Opens 10 Feb 2027
The EU's Horizon Europe programme expects to make 3 awards of €7 million – €10 million each, from a total budget of €20 million. Applications close on 16 Sep 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.
- Deadline
- 16 Sep 2027 (in 305 days)
- Opens
- 10 Feb 2027
- Grant amount
- €7 million – €10 million per project
- Total budget
- €20 million
- Funding rate
- 70% for companies, 100% for non-profits Standard rule for this programme; the call can differ.
- Total budget
- €20 million
- Expected awards
- 3
- Type of action
- HORIZON Innovation Actions · HORIZON Lump Sum Grant
- Likely applicant types
- Companies, SMEs / start-ups, Non-profits, Universities & research, Public bodies From source categories or programme rules; the call decides.
- Funder
- Horizon Europe (HORIZON)
- Reference
- HORIZON-MISS-2027-02-CANCER-02
- Call
- HORIZON-MISS-2027-02
- Last checked
- 14 Nov 2026
Expected outcome
Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
• Patients afflicted by lung, bowel, breast or prostate cancer [1] , will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures [2] .
• Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators [3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.
• National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.
Scope
Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected [4] . At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions.
Applicants should address all of the following:
• Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research on lung, bowel, breast or prostate cancer focusing on at least one of the following areas:
• Innovative diagnostics;
Read the full text
• Radiotherapy, surgery, chemotherapy;
• Therapeutic cancer vaccines for the treatment of cancer patients with early-stage, advanced, metastatic or minimal residual disease (e.g. after debulking by surgery, chemotherapy, radiotherapy, or immunotherapy);
• Implementation of appropriate clinical practice guidelines for diagnosis and treatment in countries without or with limited Comprehensive Cancer Infrastructures;
• Comprehensive cancer infrastructures should extensively pilot and upscale innovative diagnostic or treatment programmes in at least four different EU Member States or Associated Countries. One of the four targeted EU Member States or Associated Countries should represent a country without or with a less developed comprehensive cancer infrastructure.
• To ensure that together they address - and whenever feasible - overcome challenges because of the national, regional, or local research and healthcare context (e.g. those faced by small(er) EU Member States, or due to a large rural population, or particular cancer burden, socio-economic or environmental situation, or limited clinical research capacity [5] ), when designing and conducting innovative clinical research programmes with added value for the timely diagnosis and treatment of patients with lung, bowel, breast or prostate cancer;
• Identify additional resources through the European Regional Development Fund (ERDF), the Technical Support Instrument [6] , the Resilience and Recovery Facility (RRF), philanthropy, the European Investment Bank Group (EIB [7] , EIF [8] ) or any other initiative;
• Innovative clinical research programmes should be defined together with patients and their caregivers/families using participative research models and adapted to the needs of the target population and the specificities of healthcare provision at local, regional, or national level, duly reflecting the (cultural) diversity and available resources across EU Member States and Associated Countries;
• Data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of…
Who can apply
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Applicant categories are a starting point. The official call decides eligibility.
Topics
Anticancer therapy Clinical medicine Digital data Gender in basic medicine Personalised medicine Radiology, nuclear medicine and medical imaging Translational medicine Cancer centre Clinical Trial Centre Comprehensive Cancer Centre Diagnostic facilities Hospital Medical Centre Oncology Department
Timing
Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
How to apply
- Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
- Register each participating organisation in the Funding & Tenders Portal to get a PIC.
- Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
- Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
- Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | 16 September 2027 “Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).” | official data field | 15 Nov 2026 |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | €20 million | official data field | 15 Nov 2026 |
| Funding rate | 70% for companies, 100% for non-profits | programme standard rule | 15 Nov 2026 |
| Who can apply | Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule). | programme standard rule | 15 Nov 2026 |
| Where to apply | Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route. | read from the official text | 15 Nov 2026 |
Official sources
Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from Horizon Europe
Horizon Europe European Union
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe European Union
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe European Union
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe European Union
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…